Patents by Inventor Timothy Hoffman
Timothy Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11458138Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.Type: GrantFiled: April 26, 2018Date of Patent: October 4, 2022Assignee: Novartis AGInventors: Dirk Behnke, Frada Berenshteyn, Xueshi Hao, Timothy Hoffman, Qihui Jin, Arnaud Lacoste, Cameron Lee, Jun Liu, Yahu Liu, Juergen Klaus Maibaum, Tingting Mo, Jianfeng Pan, Xin Qu, Jan Tchorz, Yun Feng Xie, Shanshan Yan, Yefen Zou
-
Patent number: 10844068Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.Type: GrantFiled: July 24, 2019Date of Patent: November 24, 2020Assignee: Novartis AGInventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
-
Publication number: 20190345166Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.Type: ApplicationFiled: July 24, 2019Publication date: November 14, 2019Inventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
-
Patent number: 10407431Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.Type: GrantFiled: February 27, 2018Date of Patent: September 10, 2019Assignee: Novartis AGInventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
-
Publication number: 20180344738Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.Type: ApplicationFiled: April 26, 2018Publication date: December 6, 2018Inventors: Dirk BEHNKE, Frada BERENSHTEYN, Xueshi HAO, Timothy HOFFMAN, Qihui JIN, Arnaud LACOSTE, Cameron LEE, Jun LIU, Yahu LIU, Juergen Klaus MAIBAUM, Tingting MO, Jianfeng PAN, Xin QU, Jan TCHORZ, Yun Feng XIE, Shanshan YAN, Yefen ZOU
-
Publication number: 20180186802Abstract: The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.Type: ApplicationFiled: February 27, 2018Publication date: July 5, 2018Inventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
-
Patent number: 9944649Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.Type: GrantFiled: April 29, 2015Date of Patent: April 17, 2018Assignee: Novartis AgInventors: Alex Cortez, Timothy Hoffman, Yongkai Li, Tom Yao-Hsiang Wu, Xiaoyue Zhang
-
Publication number: 20170044168Abstract: The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.Type: ApplicationFiled: April 29, 2015Publication date: February 16, 2017Applicant: NOVARTIS AGInventors: Alex CORTEZ, Timothy HOFFMAN, Yongkai LI, Tom Yao-Hsiang WU, Xiaoyue ZHANG
-
Publication number: 20080194681Abstract: Disclosed herein are carbonyl compounds of Formula: (I) as described herein. Compounds as modulators of his-tone deacetylase (HDAC), pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.Type: ApplicationFiled: December 9, 2005Publication date: August 14, 2008Applicant: Kalypsys, Inc.Inventors: James Malecha, Stewart Noble, Christian Hassig, Paul Wash, Brandon Wiley, Charles Lawrence, Timothy Hoffman, Celine Bonnefous, NIcholas Smith
-
Publication number: 20070135431Abstract: Disclosed herein are carbonyl compounds of having the structural formula: or a salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.Type: ApplicationFiled: December 8, 2006Publication date: June 14, 2007Applicant: KALYPSYS, INCInventors: Nicholas Smith, Celine Bonnefous, Joseph Payne, Timothy Hoffman, Paul Wash, Christian Hassig, Shawn Scranton
-
Publication number: 20070065362Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.Type: ApplicationFiled: November 3, 2006Publication date: March 22, 2007Inventors: Timothy Hoffman, Wynn Volkert, Ning Li, Gary Sieckman, Chrys-Ann Higginbotham
-
Publication number: 20070027184Abstract: Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.Type: ApplicationFiled: July 27, 2006Publication date: February 1, 2007Inventors: James Malecha, Stewart Noble, Brandon Wiley, Timothy Hoffman, Celine Bonnefous, Michael Sertic, Paul Wash, Nicholas Smith, Christian Hassig, Shawn Scranton, Joseph Payne, Jeffery Hager
-
Publication number: 20060067886Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.Type: ApplicationFiled: November 4, 2005Publication date: March 30, 2006Inventors: Timothy Hoffman, Wynn Volkert, Gary Sieckman, Charles Smith, Hariprasad Gali
-
Publication number: 20060038379Abstract: Abstract of the Disclosure A travel trailer configured to be coupled to and towed by a vehicle is provided. The travel trailer has a compartment that is attached to a chassis which includes a front end and a rear end. A plurality of wheels are attached to the chassis adjacent the rear end, and a hitch assembly is attached to the chassis adjacent the front end. The compartment at the front end of the chassis forms first and second corners. A recess, directed inwardly toward the interior of the compartment, is located at each corner of the compartment. Cavities formed by each recess may receive a portion of the vehicle while the vehicle is engaged in a turn.Type: ApplicationFiled: March 28, 2005Publication date: February 23, 2006Applicant: Heartland Recreational Vehicles, LLCInventors: Brian Brady, John Rhymer, Douglas Lantz, Timothy Hoffman, Scott Tuttle
-
Publication number: 20060030543Abstract: Disclosed herein are carbonyl compounds of Formula I as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.Type: ApplicationFiled: June 9, 2005Publication date: February 9, 2006Inventors: James Malecha, Stewart Noble, Christian Hassig, Paul Wash, Brandon Wiley, Charles Lawrence, Timothy Hoffman
-
Publication number: 20060030554Abstract: Disclosed herein are carbonyl compounds of having the structural formula: or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.Type: ApplicationFiled: June 9, 2005Publication date: February 9, 2006Inventors: James Malecha, Stewart Noble, Christian Hassig, Paul Wash, Brandon Wiley, Charles Lawrence, Timothy Hoffman
-
Patent number: 6989158Abstract: There is provided a complex for use as a therapeutic pharmaceutical, the complex has a ligand containing at least one hydroxyalkyl phosphine donor group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of treating cancer by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of preventing the metastasis of cancer and arresting cell growth by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex.Type: GrantFiled: June 23, 2000Date of Patent: January 24, 2006Assignee: The Curators of the University of MissouriInventors: Kattesh V. Katti, Wynn A. Volkert, Timothy Hoffman
-
Publication number: 20050163710Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.Type: ApplicationFiled: December 29, 2004Publication date: July 28, 2005Inventors: Timothy Hoffman, Wynn Volkert, Ning Li, Gary Sieckman, Chrys-Ann Higginbotham
-
Publication number: 20030232013Abstract: The present invention provides methods of targeting breast cancer, prostate cancer, pancreatic cancer or melanoma cells using ST peptides. These methods permit both diagnostic evaluation and therapeutic intervention using appropriate conjugates.Type: ApplicationFiled: February 20, 2003Publication date: December 18, 2003Inventors: Gary Sieckman, Wynn Volkert, Leonard Forte, Timothy Hoffman, Hariprasad Gali